SITE-DIRECTED MODIFICATION OF FVIII FVIII

This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.

Saved in:
Bibliographic Details
Main Authors TJANDRA, HENDRI, MEI, BAISONG, BARNETT, THOMAS, MURPHY, JOHN, E, CHEN, JIANMIN, WANG, DEQIAN, STRAUSS, JONATHAN, S, TANG, LIANG, PAN, CLARK, Q
Format Patent
LanguageEnglish
Published 23.01.2009
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
Bibliography:Application Number: HK20080107795